Mar. 9 at 9:24 PM
$SLS Rare and unusual investment opportunity, where the Independent Data Monitoring Committee -Unblinded- actual Median Overall Survival and Immune Response data from the Interim Analysis in this ongoing Pivotal Phase 3 trial.
And while we are seeing Miraculous ALL Pooled Survival, Aza+VEN the BAT (Best Available Treatment) for Control Arm Patients, recently Failed 3 Large Phase 3 Trials, including 2 for AML Remission Maintenance.
Since the IDMC unblinded MOS and IR data - SLS Mcap has increased from .1b to 1.b and is headed to 40.b+
SLS cash increased from
$13.8M to +/-
$100M +
$80-
$100M more in the money warrant Cash, + 3 Rare Priority Review Vouchers
$450M -
$750M
At least
$150M for GPS this Year.
Institutional Funds interested increased from 39 to 150+/-
Share Price has been doing exactly what you'd expect, as we are in the Imminent zone - p3 results are coming.
Industry Players, Fund Analysts, Big Pharma
$ABBV $BMY know precisely how their drugs fare in AML CR2.
Long Money Knows
